Cargando…

A real-world study of combined modality therapy for early-stage Hodgkin lymphoma: too little treatment impacts outcome

Multiple clinical trials have assessed de-escalation strategies from combined modality therapy (CMT) to chemotherapy-alone for the treatment of early-stage classical Hodgkin lymphoma (cHL), confirming similar outcomes. The application of these data to the real-world is limited, however. We conducted...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chohan, Karan L., Young, Jason R., Lester, Scott, Alhaj Moustafa, Muhamad, Rosenthal, Allison, Tun, Han W., Hoppe, Bradford S., Johnston, Patrick B., Micallef, Ivana N., Habermann, Thomas M., Ansell, Stephen M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology 2022
Materias:	Clinical Trials and Observations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9327542/ https://www.ncbi.nlm.nih.gov/pubmed/35617689 http://dx.doi.org/10.1182/bloodadvances.2022007363

Ejemplares similares

End-of-treatment PET in early-stage Hodgkin lymphoma: valuable in addition to interim PET
por: Chohan, Karan L., et al.
Publicado: (2022)

Nivolumab and brentuximab vedotin with or without bendamustine for R/R Hodgkin lymphoma in children, adolescents, and young adults
por: Harker-Murray, Paul, et al.
Publicado: (2023)

Zanubrutinib monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma
por: Phillips, Tycel, et al.
Publicado: (2022)

Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study
por: Ansell, Stephen M., et al.
Publicado: (2023)

Pharmacodynamics and molecular correlates of response to glofitamab in relapsed/refractory non-Hodgkin lymphoma
por: Bröske, Ann-Marie E., et al.
Publicado: (2022)

Outcomes of Patients With Classic Hodgkin Lymphoma Who Relapsed After Autologous Stem Cell Transplant
por: Tun, Aung M., et al.
Publicado: (2023)

Brentuximab vedotin plus doxorubicin and dacarbazine in nonbulky limited-stage classical Hodgkin lymphoma
por: Abramson, Jeremy S., et al.
Publicado: (2022)

Polatuzumab vedotin with infusional chemotherapy for untreated aggressive B-cell non-Hodgkin lymphomas
por: Lynch, Ryan C., et al.
Publicado: (2022)

Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma
por: Zinzani, Pier Luigi, et al.
Publicado: (2022)

Pretherapy metabolic tumor volume is associated with response to CD30 CAR T cells in Hodgkin lymphoma
por: Voorhees, Timothy J., et al.
Publicado: (2022)

Feasibility of high-dose methotrexate administered on day 1 of (R)CHOP in aggressive non-Hodgkin lymphomas
por: Fleming, Megan, et al.
Publicado: (2022)

Tumor-associated antigen–specific T cells with nivolumab are safe and persist in vivo in relapsed/refractory Hodgkin lymphoma
por: Dave, Hema, et al.
Publicado: (2022)

Hodgkin lymphoma and female fertility: a multicenter study in women treated with doxorubicin, bleomycin, vinblastine, and dacarbazine
por: Machet, Antoine, et al.
Publicado: (2022)

Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma
por: Armand, Philippe, et al.
Publicado: (2023)

A novel comorbidity score for older adults with non-Hodgkin lymphoma: the 3-factor risk estimate scale
por: Gordon, Max J., et al.
Publicado: (2023)

Sequential pembrolizumab and AVD are highly effective at any PD-L1 expression level in untreated Hodgkin lymphoma
por: Allen, Pamela B., et al.
Publicado: (2022)

Role of radiotherapy to bulky sites of advanced Hodgkin lymphoma treated with ABVD: final results of FIL HD0801 trial
por: Ricardi, Umberto, et al.
Publicado: (2021)

Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma
por: Perry, C., et al.
Publicado: (2021)

Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma
por: Scordo, Michael, et al.
Publicado: (2023)

Ibrutinib plus RICE or RVICI for relapsed/refractory mature B-cell non-Hodgkin lymphoma in children and young adults: SPARKLE trial
por: Burke, G. A. Amos, et al.
Publicado: (2022)

Successful Non-Transplant Treatment of Double Hit Richter Transformation with Long-Term Remission
por: Seegobin, Karan, et al.
Publicado: (2021)

Too Little Sleep
Publicado: (1872)

Consolidative radiotherapy for residual fluorodeoxyglucose activity on day +30 post CAR T-cell therapy in non-Hodgkin lymphoma
por: Saifi, Omran, et al.
Publicado: (2023)

COVID-19: too little, too late?
por: The Lancet
Publicado: (2020)

Natalizumab for GVHD: too little or too late?
por: Quann, Kevin, et al.
Publicado: (2023)

The Opioid Crisis in America: Too much, too little, too late
por: Koenig, Kristi L.
Publicado: (2018)

Trace Minerals and Livestock: Not Too Much Not Too Little
por: López-Alonso, Marta
Publicado: (2012)

Too little too late: Waiting for TB to come
por: Kawamura, L. Masae
Publicado: (2018)

Correction of scientific literature: Too little, too late!
por: Besançon, Lonni, et al.
Publicado: (2022)

Danger of Eating Too Little
Publicado: (1874)

Reducing Cardiovascular Risk: Too Little, Too Late, Too Short-Term
por: Gray, David
Publicado: (2005)

Severe Insulin Resistance in a Patient Treated With Nivolumab and Brentuximab-Vedotin for Hodgkin Lymphoma
por: Tama, Elif, et al.
Publicado: (2023)

Chiropractic care for children: too much, too little or not enough?
por: French, Simon D, et al.
Publicado: (2010)

Oral Iron Prophylaxis in Pregnancy: Not Too Little and Not Too Much!
por: Milman, Nils
Publicado: (2012)

Timing of norepinephrine in septic patients: NOT too little too late
por: Rachoin, Jean-Sebastien, et al.
Publicado: (2014)

Reperfusion and Time to Presentation in Women: Too Little Too Late
por: Pande, Ashvin N., et al.
Publicado: (2019)

Radiology in the Undergraduate Medical Curriculum: Too Little, Too Late?
por: Dmytriw, Adam A., et al.
Publicado: (2015)

Prolonged early antimicrobials in ELBWs: Too much for too little.
por: Wynn, James L.
Publicado: (2019)

SARS-CoV and IFN: Too Little, Too Late
por: Kindler, Eveline, et al.
Publicado: (2016)

Too Little of a Good Thing
por: Templeton, J. G.
Publicado: (1885)

Cannot write session to /tmp/vufind_sessions/sess_j8smpqvbk1ee7oa7sfu66h66bp